Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Viking Therapeutics (NASDAQ:VKTX) and other developers of oral weight loss drugs traded sharply higher on Tuesday after ...

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $1.95 billion, announced today the appointment of Jon P. Stonehouse to its Board of Directors and Matthew ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid ...

Based on current operating plans, Metsera (MTSR) estimates its existing cash and cash equivalents of $352.4 at year end, together with the net proceeds from the IPO, will be sufficient to fund our ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Metsera , Inc. (NASDAQ:MTSR), a pharmaceutical company with a market capitalization of $1.95 billion, announced today the appointment of Jon P. Stonehouse to its Board of Directors and Matthew Lang as ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...